Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACLX Arcellx	$66.51 +0.5%	$61.76	$47.86 ▼ $107.37	$3.67B	0.28	605,718 shs	411,128 shs
FMTX Forma Therapeutics	$20.01	$20.00	$4.95 ▼ $20.68	$957.54M	-0.94	847,595 shs	1 shs
KRYS Krystal Biotech	$140.33 +0.5%	$147.52	$122.80 ▼ $219.34	$4.06B	0.65	305,579 shs	429,044 shs
SWTX SpringWorks Therapeutics	$46.76 +0.0%	$43.64	$28.21 ▼ $62.00	$3.52B	0.7	2.35 million shs	4.76 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACLX Arcellx	-0.66%	+1.05%	+11.21%	-7.56%	+22.54%
FMTX Forma Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
KRYS Krystal Biotech	+1.02%	+5.75%	+0.14%	-21.28%	-21.33%
SWTX SpringWorks Therapeutics	+0.02%	+0.09%	+1.37%	-6.07%	+20.12%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACLX Arcellx	2.8141 of 5 stars	3.5	3.0	0.0	0.0	3.3	2.5	0.0
FMTX Forma Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	4.6943 of 5 stars	3.5	1.0	0.0	4.7	3.9	3.3	1.9
SWTX SpringWorks Therapeutics	1.5872 of 5 stars	3.1	2.0	0.0	0.0	2.6	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACLX Arcellx	3.07	Buy	$111.33	67.39% Upside
FMTX Forma Therapeutics	0.00	N/A	N/A	N/A
KRYS Krystal Biotech	3.00	Buy	$211.13	50.45% Upside
SWTX SpringWorks Therapeutics	2.13	Hold	$52.57	12.43% Upside

Current Analyst Ratings Breakdown

Latest FMTX, KRYS, ACLX, and SWTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/16/2025	KRYS Krystal Biotech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$215.00 ➝ $155.00
5/12/2025	SWTX SpringWorks Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$47.00 ➝ $47.00
5/9/2025	ACLX Arcellx	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$133.00 ➝ $93.00
5/7/2025	KRYS Krystal Biotech	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$195.00 ➝ $189.00
5/7/2025	KRYS Krystal Biotech	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$219.00 ➝ $219.00
5/6/2025	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$240.00 ➝ $240.00
4/30/2025	SWTX SpringWorks Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$74.00 ➝ $47.00
4/29/2025	SWTX SpringWorks Therapeutics	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold
4/29/2025	SWTX SpringWorks Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$66.00 ➝ $47.00
4/28/2025	SWTX SpringWorks Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$77.00 ➝ $47.00
4/28/2025	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$221.00 ➝ $240.00

(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACLX Arcellx	$76.81M	47.72	N/A	N/A	$9.97 per share	6.67
FMTX Forma Therapeutics	$100.56M	9.52	N/A	N/A	$10.51 per share	1.90
KRYS Krystal Biotech	$333.45M	12.16	$3.56 per share	39.38	$32.85 per share	4.27
SWTX SpringWorks Therapeutics	$219.67M	16.04	N/A	N/A	$10.01 per share	4.67

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACLX Arcellx	-$70.69M	-$2.99	N/A	N/A	N/A	-25.94%	-8.28%	-5.21%	8/14/2025 (Estimated)
FMTX Forma Therapeutics	-$172.96M	-$4.00	N/A	N/A	N/A	N/A	-39.68%	-35.33%	N/A
KRYS Krystal Biotech	$10.93M	$4.16	46.93	13.92	N/A	30.69%	11.41%	10.40%	8/4/2025 (Estimated)
SWTX SpringWorks Therapeutics	-$325.10M	-$3.41	N/A	N/A	N/A	-134.73%	-46.74%	-41.12%	8/6/2025 (Estimated)

Latest FMTX, KRYS, ACLX, and SWTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/9/2025	Q1 2025	SWTX SpringWorks Therapeutics	-$0.81	-$1.11	-$0.30	-$1.11	$64.19 million	$49.09 million
5/8/2025	Q1 2025	ACLX Arcellx	-$0.84	-$1.13	-$0.29	-$1.13	$19.51 million	$8.13 million
5/6/2025	Q1 2025	KRYS Krystal Biotech	$1.38	$1.20	-$0.18	$1.20	$98.66 million	$88.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACLX Arcellx	N/A	N/A	N/A	N/A	N/A
FMTX Forma Therapeutics	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
SWTX SpringWorks Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACLX Arcellx	N/A	4.29	4.29
FMTX Forma Therapeutics	N/A	12.74	12.74
KRYS Krystal Biotech	N/A	7.28	7.76
SWTX SpringWorks Therapeutics	N/A	6.16	6.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACLX Arcellx	96.03%
FMTX Forma Therapeutics	87.39%
KRYS Krystal Biotech	86.29%
SWTX SpringWorks Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ACLX Arcellx	8.35%
FMTX Forma Therapeutics	5.79%
KRYS Krystal Biotech	13.70%
SWTX SpringWorks Therapeutics	7.83%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACLX Arcellx	80	55.11 million	50.70 million	Optionable
FMTX Forma Therapeutics	166	47.85 million	45.08 million	Not Optionable
KRYS Krystal Biotech	210	28.90 million	24.71 million	Optionable
SWTX SpringWorks Therapeutics	230	75.35 million	68.73 million	Optionable

FMTX, KRYS, ACLX, and SWTX Headlines

Recent News About These Companies

SpringWorks Therapeutics (NASDAQ:SWTX) Sees Large Volume Increase - What's Next?

June 9 at 12:46 PM | marketbeat.com

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Sold by Squarepoint Ops LLC

June 5, 2025 | marketbeat.com

RFG Advisory LLC Takes $3.93 Million Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

June 4, 2025 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 19,315 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

June 4, 2025 | marketbeat.com

SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX

June 3, 2025 | businesswire.com

Nuveen Asset Management LLC Has $6.64 Million Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

May 31, 2025 | marketbeat.com

BNP Paribas Financial Markets Makes New $351,000 Investment in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

May 28, 2025 | marketbeat.com

SpringWorks Therapeutics (SWTX) Surged on Acquisition News

May 27, 2025 | msn.com

SpringWorks Therapeutics’ SWOT analysis: biotech stock faces acquisition challenges

May 27, 2025 | investing.com

SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease

May 26, 2025 | zacks.com

ProShare Advisors LLC Has $827,000 Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

May 26, 2025 | marketbeat.com

Deutsche Bank AG Increases Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

May 25, 2025 | marketbeat.com

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Receives Consensus Recommendation of "Hold" from Analysts

May 25, 2025 | marketbeat.com

Palisades Investment Partners LLC Buys 12,154 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

May 24, 2025 | marketbeat.com

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Sold by Bank of America Corp DE

May 24, 2025 | marketbeat.com

SpringWorks gets EU endorsement for genetic disorder treatment

May 23, 2025 | msn.com

SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN

May 23, 2025 | globenewswire.com

Woodline Partners LP Buys 108,512 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

May 22, 2025 | marketbeat.com

Zimmer Partners LP Buys New Shares in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

May 22, 2025 | marketbeat.com

Velan Capital Investment Management LP Makes New $6.70 Million Investment in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

May 21, 2025 | marketbeat.com

Rafferty Asset Management LLC Has $4.44 Million Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

May 21, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Analysts Think These Stocks Could More Than Double in Value
By Nathan Reiff | May 23, 2025
View Analysts Think These Stocks Could More Than Double in Value
Intel’s Turnaround May Be the Best Bet No One’s Watching
By Jeffrey Neal Johnson | May 30, 2025
View Intel’s Turnaround May Be the Best Bet No One’s Watching
Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore
By Sam Quirke | May 14, 2025
View Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore

FMTX, KRYS, ACLX, and SWTX Company Descriptions

Arcellx NASDAQ:ACLX

$66.51 +0.34 (+0.51%)

As of 04:00 PM Eastern

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Forma Therapeutics NASDAQ:FMTX

Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S.

Krystal Biotech NASDAQ:KRYS

$140.33 +0.71 (+0.51%)

As of 04:00 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

SpringWorks Therapeutics NASDAQ:SWTX

$46.76 +0.01 (+0.02%)

As of 04:00 PM Eastern

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time